Literature DB >> 28791369

Cepharanthine hydrochloride reverses P‑glycoprotein-mediated multidrug resistance in human ovarian carcinoma A2780/Taxol cells by inhibiting the PI3K/Akt signaling pathway.

Chen-Zheng Huang1, Ya-Feng Wang2, Yan Zhang3, You-Mei Peng3, Yi-Xian Liu3, Fang Ma3, Jin-Hua Jiang3, Qing-Duan Wang3.   

Abstract

Ovarian cancer has the highest mortality rate among gynecologic malignant tumors. The major obstacle to treatment success is multidrug resistance (MDR) to chemotherapy drugs. Cepharanthine hydrochloride (CH), a natural alkaloid-derived compound, has shown MDR reversal potency in several tumor cell lines; however, the molecular mechanism is not entirely known. In the present study, we assessed whether CH sensitized malignant cells to chemotherapy drugs in ovarian cancer and explored the relevant mechanism. We found that CH reduced the IC50 value of paclitaxel and increased intracellular rhodamine-123 accumulation in human ovarian cancer A2780/Taxol cells in a concentration-dependent manner. Reverse transcription polymerase chain reaction and western blot assay demonstrated that CH inhibited MDR1 expression as indicated by reduced mRNA and protein levels in A2780/Taxol cells. In addition, the inhibitory effect was strengthened after CH was combined with the specific PI3K/Akt signaling pathway inhibitor LY294002. Furthermore, p‑Akt expression decreased gradually with the concentration of CH (2, 4 and 8 µM). Taken together, these findings indicated that CH reversed P‑glycoprotein-mediated MDR in A2780/Taxol cells by inhibiting the PI3K/Akt signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28791369     DOI: 10.3892/or.2017.5879

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  8 in total

1.  Overexpression of ABCB1 and ABCG2 contributes to reduced efficacy of the PI3K/mTOR inhibitor samotolisib (LY3023414) in cancer cell lines.

Authors:  Chung-Pu Wu; Cheng-Yu Hung; Sabrina Lusvarghi; Yang-Hui Huang; Pin-Jung Tseng; Tai-Ho Hung; Jau-Song Yu; Suresh V Ambudkar
Journal:  Biochem Pharmacol       Date:  2020-07-04       Impact factor: 5.858

Review 2.  Natural Products in Preventing Tumor Drug Resistance and Related Signaling Pathways.

Authors:  Chuansheng Yang; Zhikai Mai; Can Liu; Shuanghong Yin; Yantao Cai; Chenglai Xia
Journal:  Molecules       Date:  2022-05-30       Impact factor: 4.927

Review 3.  Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine.

Authors:  Hua Luo; Chi Teng Vong; Hanbin Chen; Yan Gao; Peng Lyu; Ling Qiu; Mingming Zhao; Qiao Liu; Zehua Cheng; Jian Zou; Peifen Yao; Caifang Gao; Jinchao Wei; Carolina Oi Lam Ung; Shengpeng Wang; Zhangfeng Zhong; Yitao Wang
Journal:  Chin Med       Date:  2019-11-06       Impact factor: 5.455

Review 4.  PI3K-AKT-mTOR and NFκB Pathways in Ovarian Cancer: Implications for Targeted Therapeutics.

Authors:  Alia Ghoneum; Neveen Said
Journal:  Cancers (Basel)       Date:  2019-07-05       Impact factor: 6.639

Review 5.  Cepharanthine: An update of its mode of action, pharmacological properties and medical applications.

Authors:  Christian Bailly
Journal:  Phytomedicine       Date:  2019-05-10       Impact factor: 5.340

6.  Targeting the PI3K/AKT/mTOR/NFκB Axis in Ovarian Cancer.

Authors:  Alia Ghoneum; Ammar Yasser Abdulfattah; Neveen Said
Journal:  J Cell Immunol       Date:  2020

7.  Role of the MUC1-C oncoprotein in the acquisition of cisplatin resistance by urothelial carcinoma.

Authors:  Keisuke Shigeta; Masanori Hasegawa; Eiji Kikuchi; Yota Yasumizu; Takeo Kosaka; Ryuichi Mizuno; Shuji Mikami; Akira Miyajima; Donald Kufe; Mototsugu Oya
Journal:  Cancer Sci       Date:  2020-08-11       Impact factor: 6.716

8.  Cajanol Sensitizes A2780/Taxol Cells to Paclitaxel by Inhibiting the PI3K/Akt/NF-κB Signaling Pathway.

Authors:  Ming Sui; Hairong Yang; Mingqi Guo; Wenle Li; Zheng Gong; Jing Jiang; Peiling Li
Journal:  Front Pharmacol       Date:  2021-12-08       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.